Back to results
US 2023/0399299 A1Published application
Aldh-2 inhibitor compounds and methods of use
AssigneeAmygdala Neurosciences, Inc.
InventorBrent Blackburn
Life of this patent
Estimating the term…
Abstract
Disclosed herein are aldehyde dehydrogenase (ALDH-2) inhibitor compounds, such as a compounds of Formula (I) or Formula (II), pharmaceutical compositions comprising these inhibitor compounds, and uses of these compounds and compositions, such as in the methods for safely treating chemical dependency on a substance or condition of addiction, such as alcohol, nicotine, cocaine, opiates, amphetamines, and compulsive eating disorder, and/or anxiety disorder, each individually or concurrent.
Claims20
A compound of Formula (I):
- wherein:
- X1 is N or CR3, X2 is N or CR4, X3 is N or CR6, with the provisos that no more than one of X1, X2, and X3 is N;
- each of X4, and X5 is independently N or CR10;
- R11 is H, halogen, optionally substituted C1-6 alkyl, or cycloalkyl;
- R7 is H, or optionally substituted C1-6 alkyl;
- each of R2, R3, R4, R5, R6, R8, R9, and R10 is independently H, halogen, —CF3, —OH, —CH2OH, —CN, optionally substituted alkyl, optionally substituted alkylene, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heterocyclyl, aminocarbonyl, acyl, acylamino, —O—(C1 to C6-alkyl)-O—(C1 to C6-alkyl), —CH2OP(O)(OR20)(OR21), —SO2NR24R25;
- or —NR24R25, with the proviso that R2 and R6 are not both Cl when X1 is CR3, X2 is CR4, X3 is CR6, X4 is CR10, X5 are CR10, and R11 is H;
- each of R20 and R21 is independently Na+, Li+, K+, hydrogen, C1-6 alkyl;
- or R20 and R21 can be combined to represent a single divalent cation Zn2+, Ca2+, or Mg2+;
- and
- each of R24 and R25 is independently chosen from hydrogen or C1-6 alkyl or when combined together with the nitrogen to which they are attached form a heterocycle;
- or a pharmaceutically acceptable salt, ester, single stereoisomer, mixture of stereoisomers, or a tautomer thereof.
9 more elements
A compound of structural Formula (II):
- wherein,
- each of X2 and X3 are independently N or CH;
- R11 is H, halogen, optionally substituted C1-6 alkyl, or cycloalkyl;
- R1 is selected from
- each of R2, and R6, is independently H, Br, Cl, F, CH3, or CF3;
- and
- each of R3, R4, and R5, is independently H, Br, Cl, F, CH3, CF3, —OH, —CH2OH, —CN, optionally substituted alkyl, optionally substituted alkylene, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heterocyclyl, aminocarbonyl, acyl, acylamino, —O—(C1 to C6-alkyl)-O—(C1 to C6-alkyl), —CH2OP(O)(OR20)(OR21), —SO2NR24R25;
- or —NR24R25, with the proviso that R2 and R6 are not both Cl when R1 is an aromatic ring, X2 and X3 are CH, and R11 is H;
- or a pharmaceutically acceptable salt, ester, single stereoisomer, mixture of stereoisomers, or a tautomer thereof.
6 more elements
Dependencies are inferred from the claim text.